Profile data is unavailable for this security.
About the company
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
- Revenue in USD (TTM)81.00k
- Net income in USD-46.45m
- Incorporated2013
- Employees49.00
- LocationActinium Pharmaceuticals Inc100 Park Ave., 23Rd FloorNEW YORK 10017United StatesUSA
- Phone+1 (646) 677-3870
- Fax+1 (845) 818-3588
- Websitehttps://www.actiniumpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Codexis Inc | 74.23m | -65.13m | 244.83m | 174.00 | -- | 3.09 | -- | 3.30 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Boundless Bio Inc | -100.00bn | -100.00bn | 245.25m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
Agenus Inc | 161.42m | -239.61m | 250.10m | 389.00 | -- | -- | -- | 1.55 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 256.13m | 133.00 | -- | 1.39 | -- | 240.72 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Invivyd Inc | 0.00 | -206.82m | 257.72m | 94.00 | -- | 1.44 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 257.92m | 49.00 | -- | 5.80 | -- | 3,184.26 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Sanara Medtech Inc | 68.00m | -4.89m | 261.17m | 107.00 | -- | 6.03 | -- | 3.84 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
XBiotech Inc | 0.00 | -30.74m | 261.63m | 92.00 | -- | 1.25 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
TriSalus Life Sciences Inc | 21.98m | -68.07m | 262.90m | 112.00 | -- | -- | -- | 11.96 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Emergent Biosolutions Inc | 1.19bn | -565.30m | 263.06m | 1.60k | -- | 0.3962 | -- | 0.2219 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
ASP Isotopes Inc | 1.27m | -19.62m | 263.47m | 76.00 | -- | 23.52 | -- | 206.91 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 264.20m | 140.00 | -- | 34.16 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
Acrivon Therapeutics Inc | 0.00 | -64.12m | 264.62m | 58.00 | -- | 1.80 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Medifast Inc | 897.81m | 67.76m | 268.29m | 634.00 | 3.96 | 1.27 | 3.31 | 0.2988 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 268.34m | 449.00 | -- | 11.01 | -- | 14.62 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
Metagenomi Inc | 44.76m | -68.26m | 268.62m | 236.00 | -- | -- | -- | 6.00 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.58m | 5.37% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.39m | 4.75% |
District 2 Capital LPas of 31 Dec 2023 | 826.43k | 2.81% |
Geode Capital Management LLCas of 31 Mar 2024 | 595.72k | 2.03% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 550.85k | 1.87% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 230.61k | 0.78% |
Verition Fund Management LLCas of 31 Mar 2024 | 196.44k | 0.67% |
Marshall Wace LLPas of 31 Mar 2024 | 152.47k | 0.52% |
Brandywine Global Investment Management LLCas of 31 Mar 2024 | 145.60k | 0.50% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 144.47k | 0.49% |